Logo image of DBVT

DBV TECHNOLOGIES SA-SPON ADR (DBVT) Stock Fundamental Analysis

NASDAQ:DBVT - Nasdaq - US23306J2006 - ADR - Currency: USD

4.395  +0.13 (+3.17%)

After market: 4.4 +0.01 (+0.11%)

Fundamental Rating

3

Overall DBVT gets a fundamental rating of 3 out of 10. We evaluated DBVT against 572 industry peers in the Biotechnology industry. DBVT may be in some trouble as it scores bad on both profitability and health. DBVT is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

DBVT had negative earnings in the past year.
DBVT had a negative operating cash flow in the past year.
DBVT had negative earnings in each of the past 5 years.
In the past 5 years DBVT always reported negative operating cash flow.
DBVT Yearly Net Income VS EBIT VS OCF VS FCFDBVT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -50M -100M -150M

1.2 Ratios

With a Return On Assets value of -63.70%, DBVT is not doing good in the industry: 61.46% of the companies in the same industry are doing better.
Looking at the Return On Equity, with a value of -91.83%, DBVT is in line with its industry, outperforming 48.13% of the companies in the same industry.
Industry RankSector Rank
ROA -63.7%
ROE -91.83%
ROIC N/A
ROA(3y)-48.56%
ROA(5y)-53.59%
ROE(3y)-66.73%
ROE(5y)-73.48%
ROIC(3y)N/A
ROIC(5y)N/A
DBVT Yearly ROA, ROE, ROICDBVT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -20 -40 -60 -80 -100

1.3 Margins

With an excellent Gross Margin value of 95.70%, DBVT belongs to the best of the industry, outperforming 96.27% of the companies in the same industry.
In the last couple of years the Gross Margin of DBVT has remained more or less at the same level.
DBVT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 95.7%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.65%
GM growth 5Y1.43%
DBVT Yearly Profit, Operating, Gross MarginsDBVT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -500 -1K -1.5K

More info and screens

3

2. Health

2.1 Basic Checks

DBVT does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for DBVT has been increased compared to 1 year ago.
The number of shares outstanding for DBVT has been increased compared to 5 years ago.
Compared to 1 year ago, DBVT has a worse debt to assets ratio.
DBVT Yearly Shares OutstandingDBVT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M
DBVT Yearly Total Debt VS Total AssetsDBVT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M

2.2 Solvency

Based on the Altman-Z score of -0.61, we must say that DBVT is in the distress zone and has some risk of bankruptcy.
With a decent Altman-Z score value of -0.61, DBVT is doing good in the industry, outperforming 61.46% of the companies in the same industry.
DBVT has a Debt/Equity ratio of 0.09. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.09, DBVT is not doing good in the industry: 65.90% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF N/A
Altman-Z -0.61
ROIC/WACCN/A
WACC7.41%
DBVT Yearly LT Debt VS Equity VS FCFDBVT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100M -100M 200M 300M

2.3 Liquidity

DBVT has a Current Ratio of 3.29. This indicates that DBVT is financially healthy and has no problem in meeting its short term obligations.
DBVT has a Current ratio of 3.29. This is in the lower half of the industry: DBVT underperforms 61.28% of its industry peers.
A Quick Ratio of 3.29 indicates that DBVT has no problem at all paying its short term obligations.
The Quick ratio of DBVT (3.29) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 3.29
Quick Ratio 3.29
DBVT Yearly Current Assets VS Current LiabilitesDBVT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M

More info and screens

6

3. Growth

3.1 Past

DBVT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 19.64%, which is quite good.
DBVT shows a strong growth in Revenue. In the last year, the Revenue has grown by 224.69%.
Measured over the past years, DBVT shows a small growth in Revenue. The Revenue has been growing by 0.50% on average per year.
EPS 1Y (TTM)19.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-30.69%
Revenue 1Y (TTM)224.69%
Revenue growth 3Y11.73%
Revenue growth 5Y0.5%
Sales Q2Q%-49.52%

3.2 Future

The Earnings Per Share is expected to grow by 18.53% on average over the next years. This is quite good.
DBVT is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 79.69% yearly.
EPS Next Y-36.93%
EPS Next 2Y2.12%
EPS Next 3Y59.71%
EPS Next 5Y18.53%
Revenue Next Year-55.09%
Revenue Next 2Y264.61%
Revenue Next 3Y338.83%
Revenue Next 5Y79.69%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
DBVT Yearly Revenue VS EstimatesDBVT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M
DBVT Yearly EPS VS EstimatesDBVT Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -10 -20 -30

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for DBVT. In the last year negative earnings were reported.
Also next year DBVT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
DBVT Price Earnings VS Forward Price EarningsDBVT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DBVT Per share dataDBVT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4

4.3 Compensation for Growth

A more expensive valuation may be justified as DBVT's earnings are expected to grow with 59.71% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y2.12%
EPS Next 3Y59.71%

More info and screens

0

5. Dividend

5.1 Amount

DBVT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

DBV TECHNOLOGIES SA-SPON ADR

NASDAQ:DBVT (2/21/2025, 8:12:30 PM)

After market: 4.4 +0.01 (+0.11%)

4.395

+0.13 (+3.17%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A N/A
Earnings (Next)03-06 2025-03-06/amc
Inst Owners29.72%
Inst Owner Change-81.32%
Ins Owners0.14%
Ins Owner Change16.94%
Market Cap90.17M
Analysts82.86
Price Target10.36 (135.72%)
Short Float %2.07%
Short Ratio1.73
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-28.87%
Min EPS beat(2)-68.32%
Max EPS beat(2)10.57%
EPS beat(4)3
Avg EPS beat(4)13.32%
Min EPS beat(4)-68.32%
Max EPS beat(4)67%
EPS beat(8)6
Avg EPS beat(8)-2.17%
EPS beat(12)8
Avg EPS beat(12)1.62%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-20.42%
Min Revenue beat(2)-29.38%
Max Revenue beat(2)-11.45%
Revenue beat(4)2
Avg Revenue beat(4)690.02%
Min Revenue beat(4)-29.38%
Max Revenue beat(4)2602.52%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)11.68%
PT rev (3m)206.94%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-368.96%
EPS NY rev (1m)0%
EPS NY rev (3m)-368.96%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-50%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5.73
P/FCF N/A
P/OCF N/A
P/B 1.14
P/tB 1.14
EV/EBITDA N/A
EPS(TTM)-4.22
EYN/A
EPS(NY)-3.41
Fwd EYN/A
FCF(TTM)-5.04
FCFYN/A
OCF(TTM)-4.92
OCFYN/A
SpS0.77
BVpS3.86
TBVpS3.86
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -63.7%
ROE -91.83%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 95.7%
FCFM N/A
ROA(3y)-48.56%
ROA(5y)-53.59%
ROE(3y)-66.73%
ROE(5y)-73.48%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.65%
GM growth 5Y1.43%
F-Score3
Asset Turnover0.14
Health
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales 15.71%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.29
Quick Ratio 3.29
Altman-Z -0.61
F-Score3
WACC7.41%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)11.98%
Cap/Sales(5y)19.7%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)19.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-30.69%
EPS Next Y-36.93%
EPS Next 2Y2.12%
EPS Next 3Y59.71%
EPS Next 5Y18.53%
Revenue 1Y (TTM)224.69%
Revenue growth 3Y11.73%
Revenue growth 5Y0.5%
Sales Q2Q%-49.52%
Revenue Next Year-55.09%
Revenue Next 2Y264.61%
Revenue Next 3Y338.83%
Revenue Next 5Y79.69%
EBIT growth 1Y20.68%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-14.39%
EBIT Next 3Y56.49%
EBIT Next 5YN/A
FCF growth 1Y-50.17%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-51.06%
OCF growth 3YN/A
OCF growth 5YN/A